TCGX closes oversubscribed $600M fund for Asian biotech

What's the deal? TCGXDealroom has a profile for this one. Try Dealroom → has closed the TCGX Asia Life Sciences Fund I, an oversubscribed $600 million vehicle backed by international institutional investors. The healthcare firm will use it to invest in biotechnology companies based in Asia, across all stages of development.

Why now? TCGX points to what it calls the "explosive growth" of early-stage drug discovery in China. Founder and managing partner Dr. Chen Yu said Asia "has become an increasingly important source of globally competitive biotechnology innovation."

The expansion: Alongside the fund, TCGX is opening offices in Shanghai and Hong Kong to put investment teams close to the companies it is backing. The firm already operates from Palo Alto, San Francisco, and New York City.

What's the endgame? The Asia fund runs separately from TCGX's Flagship Funds, which target biotech in the US and Europe. The firm wants distinct regional strategies while sharing a global network, letting it back "differentiated biotechnology companies across the world."

The signal: A dedicated $600 million pool for Asian biotech reflects growing investor conviction in the region's science and company formation. As Dandan Dong, TCGX's managing partner in Asia, put it, the firm is seeing "exceptional growth in the quality of science, entrepreneurial talent, and company formation across the Asian biotechnology ecosystem."

Read more: businesswire.com

Image credit: Generated with Gemini